Radiation maculopathy review supports OCT surveillance and sustained anti-VEGF for post-plaque edema

After plaque brachytherapy for uveal melanoma, multimodal imaging detects macular injury, while anti-VEGF offers the best-supported treatment for established edema.

KEY POINTS

  • This narrative review examined the detection, classification, and treatment of radiation maculopathy following plaque brachytherapy for uveal melanoma, incorporating literature published between January 2000 and 24 September 2026, together with selected foundational studies. The review considered iodine-125, ruthenium-106, palladium-103, and cesium-131 plaques, as well as imaging biomarkers and treatment strategies. It was not a systematic review or meta-analysis, and studies involving proton therapy were considered separately from plaque-specific evidence.
  • Radiation maculopathy involves overlapping vascular, inflammatory, permeability, and neuronal injury rather than a single linear progression. Important risk factors include short tumor-to-fovea and tumor-to-optic-disc distances, larger tumor dimensions, higher macular or optic-disc dose, and systemic vascular comorbidities such as diabetes. Plaque isotope characteristics influence dose distribution, but differences in tumor selection, prescription, plaque geometry, and anatomical location prevent reliable conclusions that one isotope consistently produces less macular toxicity.
  • Structural optical coherence tomography (OCT) can detect macular edema before clinical funduscopic changes or visual symptoms. Early abnormalities include retinal thickening, intraretinal cysts, and occasionally subretinal fluid, whereas later manifestations include photoreceptor damage, retinal thinning, and atrophy. The Horgan OCT classification describes five grades of radiation-related macular edema, progressing from extrafoveal noncystoid edema to severe foveal cystoid edema, but does not fully capture peripheral ischemia or irreversible neuronal damage.
  • OCT angiography (OCTA) provides additional information about retinal microvascular injury, including reduced capillary density, foveal avascular zone enlargement, and abnormalities of the deep capillary plexus. A prospective study of 39 eyes after ruthenium-106 plaque therapy demonstrated reduced vessel density at one year, while another longitudinal study of 21 eyes after iodine-125 treatment identified macular and peripapillary vascular changes associated with radiation dose. However, OCTA measurements remain sensitive to signal quality, segmentation errors, cystoid edema, and device-specific acquisition parameters, and no validated treatment threshold is available.
  • Multimodal imaging remains necessary because each technique measures different aspects of radiation injury. Fluorescein angiography identifies vascular leakage and nonperfusion, while ultra-wide-field imaging extends assessment beyond the macula. Laser speckle flowgraphy showed reduced retinal and choroidal blood-flow indices in a 25-patient cross-sectional study after iodine-125 brachytherapy, but remains investigational. Importantly, reduced macular thickness after treatment does not necessarily indicate restored capillary perfusion or neuronal recovery.
  • Intravitreal anti-VEGF therapy has the strongest available evidence for established radiation-related macular edema, although treatment remains off-label. In the prospective randomized ARM study, 40 patients were enrolled to compare fixed six-week aflibercept with an adjusted regimen, with 39 completing the first year and 30 entering the second-year extension. The 40-eye randomized RRR study also evaluated ranibizumab schedules, with monthly treatment providing the strongest first-year results. These studies support repeated treatment rather than assuming durable disease control after a short injection course.
  • The evidence for prophylactic anti-VEGF treatment remains less definitive. In retrospective iodine-125 plaque cohorts, bevacizumab administered at plaque removal and every four months for two years was associated with reduced intermediate-term macular edema and radiation complications compared with historical controls. However, four-year poor-vision outcomes were not significantly improved, with approximately 61% reaching 20/200 vision or worse in both comparison groups. A separate randomized trial involving 163 patients found that periocular triamcinolone reduced OCT-detected edema through 18 months, but steroid-related cataract and intraocular-pressure risks remain relevant. Randomized plaque-specific evidence establishing long-term visual benefit from anti-VEGF prophylaxis is still lacking.

CLINICAL TAKEAWAY

After plaque brachytherapy for uveal melanoma, surveillance should integrate baseline visual function, patient-specific macular and optic-disc dosimetry, structural OCT, and complementary vascular imaging when clinically indicated. Anti-VEGF therapy offers the best-supported approach for established radiation-related macular edema, while routine prophylaxis and treatment decisions based on isolated OCTA abnormalities remain insufficiently validated.

SOURCE

Frontiers in Oncology

Browse more research Suggest a correction